Enlivex Therapeutics Gets Green Light for COVID-19 Trial
Ticker: ENLV · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, regulatory-approval, covid-19
TL;DR
Enlivex cleared for COVID-19 trial with Allocetra in Israel.
AI Summary
On June 3, 2024, Enlivex Therapeutics Ltd. announced it received regulatory authorization to begin an investigator-initiated, randomized clinical trial for its drug candidate, Allocetra, in patients with severe COVID-19. This trial will be conducted at Rabin Medical Center in Israel.
Why It Matters
This authorization marks a significant step for Enlivex's Allocetra drug, potentially validating its efficacy in treating severe COVID-19 and opening new avenues for the company's therapeutic pipeline.
Risk Assessment
Risk Level: medium — Clinical trial initiations carry inherent risks related to patient recruitment, trial outcomes, and regulatory approvals, which can impact the company's future prospects.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra (drug) — Drug candidate for COVID-19 trial
- Rabin Medical Center (company) — Location of the clinical trial
- June 3, 2024 (date) — Date of announcement
FAQ
What is the primary purpose of the newly authorized clinical trial?
The trial is an investigator-initiated, randomized study to evaluate Enlivex's drug candidate, Allocetra, in patients with severe COVID-19.
Where will the clinical trial be conducted?
The trial will be conducted at Rabin Medical Center in Israel.
What is the name of the drug candidate being tested?
The drug candidate being tested is Allocetra.
When was the regulatory authorization for the trial announced?
The announcement was made on June 3, 2024.
What type of trial design will be used?
The trial will be an investigator-initiated, randomized clinical trial.
Filing Stats: 229 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-06-03 08:05:31
Filing Documents
- ea0207157-6k_enlivex.htm (6-K) — 9KB
- ea020715701ex99-1_enlivex.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-048784.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: June 3, 2024 2